Piramal Pharma Cuts Emissions by 22.6% in Latest Sustainability Push

The Mumbai-based pharmaceutical giant has successfully integrated sustainability into its core business model, achieving a 41% renewable energy usage rate across its global operations. This performance aligns with the company’s decarbonisation roadmap, which is formally approved by the Science Based Targets initiative (SBTi). Beyond environmental metrics, the company reported significant progress in operational quality, finishing the year with zero Official Action Indicated (OAI) observations across three separate USFDA inspections.

Investment remains a central theme, highlighted by a US$90 million commitment toward expanding advanced therapeutics at facilities in Lexington and Riverview. Digital transformation efforts, spearheaded by the Catalyst NxGen and SAP S/4HANA systems, aim to solidify these gains in quality and compliance. Chairperson Nandini Piramal emphasized that these steps are not mere administrative obligations but essential components of the company's innovation agenda. With 30% female representation on the Board and ₹8.98 crore funneled into corporate social responsibility initiatives, the firm is balancing industrial expansion with social and governance benchmarks, including comprehensive ESG training for its entire workforce.